JPRN-UMIN000025454
Recruiting
未知
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes. - The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.
Dokkyo Medical University Department of Endocrinology and Metabolism0 sites20 target enrollmentDecember 28, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dokkyo Medical University Department of Endocrinology and Metabolism
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Type 1 diabetes 2\)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3\)A pregnant woman and/or a woman under breast\-feeding 4\)Impaired kidney function (serum crearinine greater than 1\.3 mg/dl in men, 1\.2 mg/dl in women) 5\)Diabetic proliferative retinopathy 6\)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7\)Cigarette smokers
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus ResearchType 2 diabetes mellitusJPRN-UMIN000031867HO Kyoto Medical Center, Diabetes Center30
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15
Active, not recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Not yet recruiting
Phase 4
The role of SGLT-2 inhibitors (Empagliflozin) in treating steroid induced hyperglycaemia in the management of glucocorticoid induced hypoerglycaemia in adults with and without diabetes.ACTRN12620000745943Endocrinology Department, Gosford Hospital30
Completed
Not Applicable
Effects of Dapagliflozin, a SGLT2 inhibitor, on Body Composition in Japanese Type 2 Diabetes Patients without severe ObesityJPRN-UMIN000029205Jinnouchi Hispital60